Research progress of new nanodrug AGUIX for radiosensitization
10.3760/cma.j.issn.1673-4181.2018.03.014
- VernacularTitle:新型放疗增敏纳米药物AGUIX的研究进展
- Author:
Hao SUN
1
;
Yan WANG
;
Chang XU
;
Liqing DU
;
Qiang LIU
Author Information
1. 300192天津,中国医学科学院北京协和医学院放射医学研究所,天津市放射医学分子核医学重点实验室
- Keywords:
AGUIX;
Gadolinium;
Radiotherapy;
Radiation sensitization;
Nanoparticles
- From:
International Journal of Biomedical Engineering
2018;41(3):271-274,280
- CountryChina
- Language:Chinese
-
Abstract:
In order to effectively improve the radiation sensitivity of tumors and reduce the side effects during radiotherapy,people have been working on the development of radiation sensitizers.In recent years,many researches focused on the nanoparticles with high atomic number elements as radiosensitizers.Researchers have recently developed a kind of new gadolinium-based radiation-sensitizing nanoparticles,i.e.AGUIX,which have low toxicity,low quality,and radiation-activated drug activity.These nanoparticles are consisted by a polysiloxane core and a network of covalently attached gadolinium chelates.They have a hydrodynamic diameter of less than 5 nm,and can be administered intravenously due to the preferential accumulation in tumor sites and elimination by kidney.Studies have proved that AGUIX can be used as a safe and effective radiation sensitizer under various irradiation conditions.In addition,due to the presence of strontium,AGUIX itself can also be used as a MRI contrast agent to monitor the biodistribution of drugs and tumor evolution,and then guide the development of radiotherapy.In this paper,the research progress of AGUIX in recent years was reviewed.
